Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cryoport, Inc. on September 17, 2013, reporting events that occurred on September 13, 2013. The filing addresses corporate governance changes, specifically the election of a new director and the appointment of committee leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The primary material change reported is the expansion of the Board of Directors:
- Board Election: Mr. Edward J. Zecchini was elected to the Board of Directors.
- Committee Appointment: Mr. Zecchini was appointed Chairman of the Nominating and Governance Committee.
- Related Party Disclosure: Mr. Zecchini is the brother-in-law of Mr. Rathmann, the Company's Chairman of the Board. The Board confirmed no other related party transactions or arrangements influenced his selection.
Compensation and Outlook
As a non-employee director, Mr. Zecchini's compensation package includes:
- Equity: An initial grant to purchase 100,000 shares of common stock under the 2011 Stock Incentive Plan.
- Cash Compensation: $40,000 annually as a director and an additional $8,000 annually for his role as Committee Chair.
The Board cited Mr. Zecchini's over thirty years of experience in healthcare and information technology as the rationale for his appointment. No specific financial guidance, risks, or contingencies were disclosed in this filing.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 100,000 share option grant on dilution.
- Review the Company's 2011 Stock Incentive Plan terms to understand vesting schedules for the new grant.
- Confirm the total annual cash compensation obligations for the Board of Directors.
- Assess the strategic value of Mr. Zecchini's specific background in IT and home healthcare relative to Cryoport's business model.